<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889874</url>
  </required_header>
  <id_info>
    <org_study_id>ANZ1601/BIG 16-02</org_study_id>
    <secondary_id>2016-003527-33</secondary_id>
    <nct_id>NCT02889874</nct_id>
  </id_info>
  <brief_title>EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer</brief_title>
  <acronym>EXPERT</acronym>
  <official_title>A Randomised Phase III Trial of Adjuvant Radiation Therapy Versus Observation Following Breast Conserving Surgery and Endocrine Therapy in Patients With Molecularly Characterised Luminal A Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breast Cancer Trials, Australia and New Zealand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Breast Cancer Trials, Australia and New Zealand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus
      observation following breast conserving surgery and planned endocrine therapy in patients
      with stage I breast cancer of luminal A subtype defined using the Prosigna (PAM50) Assay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation therapy (RT) after breast conserving surgery to improve local control and survival
      is the current standard of care for patients with early breast cancer. However, breast cancer
      is a heterogeneous disease, and the absolute benefit of RT in individual patients varies
      substantially. Thus, a pressing priority in contemporary breast cancer management is to
      tailor RT utilisation to the individual recurrence risks by identifying patients who are
      unlikely to benefit from RT, thereby avoiding the morbidity and costs of over-treatment.

      It is recognised that selected patients with early breast cancer are unlikely to derive
      benefits from RT after breast conserving surgery. However, randomised trials have not
      consistently identified patients who may safely omit RT using conventional
      clinical-pathologic characteristics.

      Breast cancer intrinsic subtypes distinguished by gene expression profiling are shown to be
      associated with distinct clinical outcomes. There is substantial evidence supporting the
      clinical validity of multigene assays including the PAM50-based Prosigna Assay that
      identifies intrinsic subtypes and generates a Risk of Recurrence score (ROR) to quantify
      individual risks of distant relapse. Multigene assays are increasingly integrated into
      clinical practice to inform chemotherapy decision, highlighting their substantial practice
      changing potential in personalising the use of RT for early breast cancer.

      A recent analysis of archived tumour specimens of 1,308 patients with early breast cancer has
      shown significant associations between local recurrence risk and the PAM50-defined intrinsic
      subtypes and ROR score. EXPERT presents a unique opportunity of clinical and public health
      importance to optimise personalised local therapy for early breast cancer through precise,
      individualised quantification of local recurrence risk to identify low-risk patients for whom
      RT after breast conserving surgery may be safely omitted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence rate after breast conserving surgery</measure>
    <time_frame>10 years</time_frame>
    <description>To determine if omission of RT is not inferior to RT in terms of local recurrence rate after breast conserving surgery in patients with stage I, biologically low-risk luminal-A subtype early breast cancer who receive adjuvant endocrine therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local-regional recurrence-free interval (LRRFI)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence-free interval (DRFI)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival including DCIS (DFS-DCIS)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive disease free survival (iDFS)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer specific survival (BCSS)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salvage RT or mastectomy rate</measure>
    <time_frame>10 years</time_frame>
    <description>each to be assessed individually and in combination as a composite endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events for patients</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse events during treatment (up to 5 years of endocrine therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact of endocrine therapy</measure>
    <time_frame>5 years</time_frame>
    <description>FACT-ES measure of endocrine symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance with endocrine therapy</measure>
    <time_frame>5 years</time_frame>
    <description>Morisky Compliance Questionnaire (MMAS-4)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life: Fear of recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Fear of Cancer Recurrence Inventory</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life: Convenience of care</measure>
    <time_frame>5 years</time_frame>
    <description>Visual Analogue Scales (convenience and impact of treatment)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1167</enrollment>
  <condition>Early Stage Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>A: Radiation Therapy &amp; endocrine therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: No Radiation Therapy (ET only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Omission of radiation therapy</intervention_name>
    <description>Omission of radiation therapy (adjuvant endocrine therapy only).</description>
    <arm_group_label>B: No Radiation Therapy (ET only)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: for registration in the study:

          1. Female patients aged ≥ 50 years of any menopausal status.

          2. Primary tumour characteristics as assessed by conventional histopathology:

               -  Unifocal histologically confirmed invasive breast carcinoma

               -  Maximum microscopic size ≤2 cm

               -  Grade 1 or 2 histology

               -  ER and PR positive in ≥10% of tumour cells in either the biopsy or breast
                  conserving surgical specimen

               -  HER2 negative on IHC (score 0 or 1+) or in situ hybridisation
                  (ERBB2-amplification Ratio ERBB2/centromeres &lt;2.0 or mean gene copy number &lt;6).
                  Equivocal IHC score (2+) must be assessed by ISH.

          3. Primary tumour must be resected by breast conserving surgery with microscopically
             negative margins for invasive carcinoma and any associated ductal carcinoma in situ
             (no cancer cells adjacent to any inked edge/surface of specimen) or re-excision
             showing no residual disease.

          4. Histologically confirmed negative nodal status determined by sentinel node biopsy or
             axillary dissection. Patients with pN0 (i+) disease are eligible for study
             participation (malignant cells ≤0.2 mm in regional lymph node(s) detected by
             hematoxylin-eosin (H&amp;E) stain or IHC, including isolated tumour cells).

          5. No evidence of distant metastasis.

          6. Eligible for and willing to have adjuvant endocrine therapy.

          7. ECOG performance status 0-2.

          8. Availability of FFPE tumour block for Prosigna (PAM50) Assay.

        For randomization to the study, patients must fulfill all of the following criteria:

        1. Primary tumour characteristics as assessed by Prosigna (PAM50) Assay:

          -  Luminal A intrinsic subtype

          -  ROR score ≤60

        Exclusion Criteria:

        Any one of the following is regarded as a criterion for exclusion from the study:

          1. Primary tumour characteristics:

               -  Presence of multifocal or multicentric invasive carcinoma or ductal carcinoma in
                  situ;

               -  Evidence of clinical or pathologic T4 disease (extension to the chest wall,
                  oedema or ulceration of skin, satellite skin nodules, inflammatory carcinoma);

               -  The invasive component of the primary tumour is present as micro-invasion only;

               -  Grade 3 histology;

               -  Presence of lymphovascular invasion

          2. Contra-indication or unwillingness to have adjuvant endocrine therapy.

          3. Planned to receive adjuvant chemotherapy or biologic therapy after breast cancer
             surgery, i.e. any systemic therapy other than endocrine therapy is not permitted. Any
             therapy unrelated to cancer is permitted at the discretion of investigators.

          4. Treated with neoadjuvant endocrine therapy, chemotherapy or biologic therapy prior to
             breast cancer surgery.

          5. Prior breast or thoracic RT for any condition.

          6. Pre-operative breast imaging evidence of disease aside from the primary carcinoma
             resected by breast conserving surgery.

          7. Concurrent invasive breast carcinoma or ductal carcinoma in situ (synchronous or
             metachronous).

          8. Prior diagnosis of invasive breast carcinoma or ductal carcinoma in situ in either
             breast irrespective of disease free interval.

          9. A diagnosis of non-breast malignancy &lt;5 years prior to randomisation with the
             following exceptions:

               -  Patients who are diagnosed with carcinoma in situ of cervix, endometrium or
                  colon; melanoma in situ; and basal or squamous cell carcinoma of the skin at any
                  time prior to randomisation are not excluded from study participation.

               -  Patients who are diagnosed with other non-breast malignancy ≥5 years prior to
                  randomisation and without evidence of disease recurrence are not excluded from
                  study participation.

         10. Significant comorbidity precluding definitive RT for breast cancer (e.g.
             cardiovascular or pulmonary disease, scleroderma, systemic lupus erythematosus).

         11. Life expectancy &lt;10 years.

         12. Documented mutation of BRCA1, BRCA2 or TP53, or at high genetic risk of breast cancer.

         13. Pregnant or lactating patients.

         14. Inability to be registered to the study ≤6 weeks after the last surgical procedure for
             breast cancer.

         15. Inability to commence RT (if randomised to receive RT) no later than 12 weeks from the
             last surgical procedure for breast cancer.

         16. Inability to provide written informed consent.

         17. Psychiatric, addictive, or any disorder that precludes compliance with protocol
             requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillipa Lee</last_name>
    <role>Study Director</role>
    <affiliation>Breast Cancer Trials, Australia and New Zealand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boon H Chua, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Prince of Wales Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heath Badger</last_name>
    <phone>+61 2 4925 5239</phone>
    <email>expert@bctrials.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Akiko Fong</last_name>
    <phone>+61 2 4925 5230</phone>
    <email>expert@bctrials.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Sullivan, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macarthur Cancer Therapy Centre</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Papadatos, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital, Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanne Toohey, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Care Newcastle</name>
      <address>
        <city>Gateshead</city>
        <state>New South Wales</state>
        <zip>2290</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter O'Brien, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hester Lieng, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Hester Lieng, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>1871</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Boxer, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Hospital Sydney</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Spillane, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Hansen, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boon H Chua, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tamworth Rural Referral Hospital</name>
      <address>
        <city>Tamworth;</city>
        <state>New South Wales</state>
        <zip>2340</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Pendlebury, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verity Ahern, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>de Leon Jeremiah, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Care Wesley</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Burke, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margot Lehman, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre - Bendigo</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solveig Grenfell, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre - Moorabin</name>
      <address>
        <city>Bentleigh East</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven David, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Devitt, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre Richmond</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew See, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Moore, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GenesisCare Radiation Oncology Centre Frankston</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Blakey, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Geelong</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Francis, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Chao, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>8006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prue Francis, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ringwood Radiation Oncology Centre</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Chao, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mandy Taylor, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa James, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Campbell, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <zip>4414</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Hardie, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Nicholson, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>https://www.breastcancertrials.org.au/home</url>
    <description>Breast Cancer Trials (formerly Australia &amp; New Zealand Breast Cancer Trials Group</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiation therapy</keyword>
  <keyword>omission</keyword>
  <keyword>non-inferiority</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>to be defined.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

